Peplin is a specialty pharmaceutical company focused on advancing and commercializing medical dermatology products.
Business Model:
Revenue: $0
Employees: 11-50
Peplin was acquired by
LEO Pharma.
The acquisition happend on 2009-09-03.
Details of the transaction were not public
Address:
City: Emeryville
State: California
Zip:
Country: United States
Peplin is a development-stage specialty pharmaceutical company focused on advancing and commercializing medical dermatology products. The Company is developing PEP005 (ingenol mebutate) (PEP005), which is derived from Euphorbia peplus (E. peplus), a plant referred to as petty spurge or radium weed. Peplin’s lead product candidate, which is in Phase III clinical trials, is a patient-applied topical gel containing PEP005, a compound used for the treatment of actinic keratosis (AK). Peplin’s other product candidate is a physician-applied topical gel for the treatment of superficial basal cell carcinoma (superficial BCC), PEP005 Gel for BCC. The active compound in each product is a small molecule extracted and purified from the sap of E. peplus. On October 16, 2008, the Company acquired Neosil, Inc., a dermatology-focused company. Later on, Peplin, Inc. was acquired by LEO Pharma A/S.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 8/2008 | Private Equity Round | 5 | $24M |
Asia Union Investments GBS Ventures MPM Capital New Enterprise Associates Orbis Investment Management Asia Union Investments GBS Ventures MPM Capital New Enterprise Associates Orbis Investment Management |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|